Sector News

Integra to buy J&J's Codman neurosurgery business for $1.05 billion

February 16, 2017
Life sciences

Medical device maker Integra LifeSciences Holdings Corp said it would buy Johnson & Johnson’s Codman neurosurgery business for $1.05 billion in cash, to expand its presence outside the United States.

Integra, which makes products used in neurosurgery, reconstruction, wound and dental care, made a “binding offer” for the Codman business, which will bolster its pipeline of offerings for tissue ablation, spinal cord repair and cranial stabilization.

The companies will finalize the deal after receiving the green light from various works councils and regulators, a J&J spokeswoman told Reuters, adding that the deal would close in the fourth quarter, if approved.

Integra said its adjusted earnings per share would increase by at least 22 cents in the first full year after closing and rise thereafter.

The deal would enable the company to generate 30 percent or more of sales from international markets, Integra executives said on a conference call.

However, Integra expects some disruption in the Codman business in the first year following the purchase, but forecast the business would grow 3-6 percent in the longer term.

The Codman neurosurgery business, which is part of J&J’s DePuy Synthes unit and markets devices for use in neuro-critical care and electrosurgery, generated sales of about $370 million in 2016.

The deal excludes Codman’s neurovascular and drug delivery businesses, J&J said.

The U.S. healthcare giant, which is buying Swiss biotech company Actelion Ltd in a $30 billion deal, said last month it was reviewing strategic options for some of its diabetes care businesses.

Integra’s shares rose as much as 6 percent to $45.87 in morning trade, while J&J’s stock was marginally up.

As of Tuesday’s close, Integra’s shares had gained about 56 percent in the past 12 months, while J&J’s stock had risen 14 percent.

If the proposed deal is not closed, DePuy is entitled to receive a termination fee of $60 million, according to a regulatory filing.

Plainsboro, New Jersey-based Integra, which hopes the transaction will accelerate its path to generate $2 billion in revenue, said it has obtained committed financing from BofA Merrill Lynch and JPMorgan.

BofA Merrill Lynch is serving as Integra’s financial adviser, while Latham & Watkins LLP is its legal adviser.

By Divya Grover

Source: Reuters

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend